Radium-223 dichloride (223 Ra) is an α-emitter radionuclide approved for treatment of
osteoblastic metastases in castrate-resistant prostate cancer (mCRPC) patients. 223 Ra …

In the last decade, many life-prolonging therapeutic options have emerged for metastatic
castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to …

Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or
drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged …

Background A computer-assisted diagnostic system for analyzing bone scans (BONENAVI)
calculates the automated bone scan index (aBSI). Here we evaluated the aBSI as a …

Objectives To evaluate the real‐world data on the efficacy and safety of a combination
therapy with radium‐223 (Ra‐223) and second‐generation androgen‐receptor targeting …

Purpose Radium-223 is an alpha-emitting radiopharmaceutical that significantly prolongs
overall survival in patients with castration-resistant prostate cancer and symptomatic bone …

Abstract 223 Radium (Ra) dichloride (Radium-223, Xofigo®; Bayer AG, Germany) is the first
targeted alpha therapy to prolong survival in adult patients with castration-resistant prostate …

Ra-223 therapy is recommended for Castration Resistant Prostate Cancer (CRPC) patients
with bone metastases. The standard protocol is 5-6 cycles of therapy with 4 weeks intervals …

Abstract 223 Radium (Ra)-Dichlorid (Radium-223, Xofigo®, Bayer AG, Leverkusen) ist die
erste gezielte Alphastrahler-Therapie zur Verlängerung des Überlebens bei erwachsenen …

El dicloruro de radio-223 es un radiofármaco emisor alfa que prolonga la supervivencia
global en pacientes con cáncer de próstata resistente a la castración y metástasis óseas …